Overview

A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2025-07-30

Target enrollment:

Participant gender:

Summary

This is a Phase 1 dose escalation and dose expansion phase I study to evaluate the safety, tolerability, pharmacokinetic profile and preliminary efficacy of RGT-419B as monotherapy in Chinese patients with HR+/HER2- advanced/metastatic breast cancer and other advanced solid tumors.

Phase:

PHASE1

Details

Lead Sponsor:

Regor Pharmaceuticals Inc.

Treatments:

Bulk Drugs